Equities

Alliance Pharma PLC

Alliance Pharma PLC

Actions
Health CarePharmaceuticals & Biotechnology
  • Price (GBX)78.10
  • Today's Change1.10 / 1.43%
  • Shares traded264.83k
  • 1 Year change21.65%
  • Beta0.7017
Data delayed at least 20 minutes, as of Dec 06 2019 15:32 GMT.
More ▼

Key statistics

As of last trade Alliance Pharma PLC (APH:LSE) traded at 78.10, -5.22% below its 52-week high of 82.40, set on Apr 15, 2019.
52-week range
Today
59.15Jan 16 201982.40Apr 15 2019
Markit short selling activity
Low
Med
High
Open78.00
High79.00
Low77.20
Bid77.20
Offer78.20
Previous close77.00
Average volume1.20m
Shares outstanding526.58m
Free float475.02m
P/E (TTM)18.80
Market cap405.46m GBP
EPS (TTM)0.041
GBP
Annual div (ADY)1.51
GBX
Annual div yield (ADY)1.96%
Div ex-dateJun 13 2019
Div pay-dateJul 11 2019
Next div ex-dateDec 19 2019
Next div pay-dateJan 10 2020
Data delayed at least 20 minutes, as of Dec 06 2019 15:32 GMT.
More ▼

Investors Chronicle View

The last IC recommendation on Alliance Pharma PLC shares was Hold at 75.00 on 25 Sep 2019Read the full article

Board of Directors

1/7

Peter Butterfield, Chief Executive Officer

2/7

John Dawson, Non-Executive Director

3/7

Nigel Clifford, Non-Executive Director

4/7

David Cook, Chairman

5/7

Andrew Franklin, Chief Financial Officer

6/7

Jo LeCouilliard, Independent Non-Executive Director

7/7

Richard Jones, Independent Non-Executive Director

Contact

Alliance Pharma plc:
Avonbridge House
Bath Road
Chippenham
Wiltshire
SN15 2BB
United Kingdom

T: +44 [0]1249 466966
F: +44 [0]1249 466977

E: info@alliancepharmaceuticals.com
E: medinfo@alliancepharma.co.uk

IR Contacts:
Please contact Peter Butterfield or Andrew Franklin at:
ir@alliancepharmaceuticals.com

2018 Preliminary Results

The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.